JPRN-UMIN000033194招募中未知
The Project for Risk Identification of Immune-Mediated Adverse Events - PRIME study
Department of Respirology, Graduate School of Medicine, Chiba University0 个研究点目标入组 300 人开始时间: 2018年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with any condition, in the opinion of the investigator, have the limitation of ability to comply with the study requirements or impact the interpretability of study results.
研究者
相似试验
未知
1 期
DNK-651-1JPRN-jRCT2080223171DENKA SEIKEN CO.,LTD.
招募中
1 期
A pilot study to evaluate the safety and efficacy of a personalised cancer vaccine in patients with completely resected early stage lung cancerLung CancerACTRN12619000769189niversity of Western Australia6
招募中
2 期
Preliminary study: Safety and Immunological Response following COVID-19 Vaccination in COVID-19 survivorsCOVID-19 survivorsCOVID-19 VaccinationTCTR20210720005Faculty of Medicine Siriraj Hospital180
尚未招募
不适用
Malaria vectored vaccines and EPI co-administration trial (VAC 058)MalariaPACTR201402000749217THE JENNER INSTITUTE, UNIVERSITY OF OXFORD65
已完成
3 期
A Comparative Phase III Clinical Study of Bharat Biotech International Limited Rabies Vaccine INDIRAB reconstituted with 1mL diluent Vs Reference Vaccine, administered Intramuscularly in healthy volunteers as Pre-Exposure treatment.CTRI/2010/091/000214Bharat Biotech International Limited,Genome Valley, Shameerpet,Ranga Reddy (Distict),Hyderabad-500 078.60